The proteome of human brain microdialysate

Maurer, Martin H.; Berger, Christian; Wolf, Margit; Fütterer, Carsten; Feldmann, Robert; Schwab, Stefan; Kuschinsky, Wolfgang

doi:10.1186/1477-5956-1-7

Cited by 60 publications

(49 citation statements)

References 30 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this investigation, only microdialysates that were collected without BSA in the perfusate were included. The total protein concentration obtained was in good agreement with the total protein concentration of approximately 0.2 mg/mL that has been found in microdialysates from the brain (Maurer et al 2003, Hillman et al 2005). Moreover, we were able to collect protein continuously over 24 h. The higher total protein concentration in the first 3-h interval can be attributed to the initial burst when starting microdialysis.…”

Section: Discussionsupporting

confidence: 85%

Monitoring of the first stages of bone healing with microdialysis

Förster¹,

Gao²,

Demmrich

et al. 2013

Acta Orthopaedica

View full text Add to dashboard Cite

Background and purpose Bone healing is a complex process influenced by growth factors, cytokines, and other mediators. The regulation of this process is not well understood. In this pilot study, we used microdialysis technology in a critical-size bone defect in rat femurs to determine the feasibility of measuring cytokines and growth factors in the first 24 h after injury.Methods A 5-mm defect, stabilized by a plate, was created in the femurs of 30 male Wistar rats. The microdialysis probe (with 100 kDa molecular weight cutoff) was inserted into the defect and microdialysates were collected continuously for up to 24 h. Total protein concentration, interleukin-6 (IL-6) concentration, and transforming growth factor-β1 (TGF-β1) concentration were assessed under different conditions.Results Microdialysis allowed continuous and consistent protein collection over 24 h from a critical-size bone defect starting at the time of injury. IL-6 was secreted within the first 3 h after the injury. The highest IL-6 concentration (344 pg/mL) was measured between 12 and 15 h after surgery. Addition of bovine serum albumin to the perfusate resulted in detectable concentrations of TGF-β1 ranging from 10 to 23 pg/mL.Interpretation Continuous sampling over 24 h of proteins from a bone defect directly after the injury is feasible and provides the opportunity for a detailed analysis of the initial stages of bone healing.

show abstract

Section: Discussionsupporting

confidence: 85%

Monitoring of the first stages of bone healing with microdialysis

Förster¹,

Gao²,

Demmrich

et al. 2013

Acta Orthopaedica

View full text Add to dashboard Cite

show abstract

“…The first description of proteomic study of microdialysis was by Maurer et al [16], and was done in ischemic stroke patients using two dimensional gel electrophoresis followed by mass spectrometry and they found 10 proteins unique to the microdialysate sample. Surprisingly, some proteins identified in Maurer’s study were larger than 20 kD which is the stipulated cut-off of the microdialysate semi-permeable membrane.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Crisis After Traumatic Brain Injury is Associated with a Novel Microdialysis Proteome

et al. 2010

View full text Add to dashboard Cite

Background To examine if the metabolic distress after traumatic brain injury (TBI) is associated with a unique proteome. Methods Patients with severe TBI prospectively underwent cerebral microdialysis for the initial 96 h after injury. Hourly sampling of metabolism was performed and patients were categorized as having normal or abnormal metabolism as evidenced by the lactate/pyruvate ratio (LPR) threshold of 40. The microdialysate was frozen for proteomic batch processing retrospectively. We employed two different routes of proteomic techniques utilizing mass spectrometry (MS) and categorized as diagnostic and biomarker identification approaches. The diagnostic approach was aimed at finding a signature of MS peaks which can differentiate these two groups. We did this by enriching for intact peptides followed by MALDI-MS analysis. For the biomarker identification approach, we applied classical bottom-up (trypsin digestion followed by LC-MS/MS) proteomic methodologies. Results Five patients were studied, 3 of whom had abnormal metabolism and 2 who had normal metabolism. By comparison, the abnormal group had higher LPR (1609 ± 3691 vs. 15.5 ± 6.8, P < 0.001), higher glutamate (157 ± 84 vs. 1.8 ± 1.4 μM, P < 0.001), and lower glucose (0.27 ± 0.35 vs. 1.8 ± 1.1 mmol/l, P < 0.001). The abnormal group demonstrated 13 unique proteins as compared with the normal group in the microdialysate. These proteins consisted of cytoarchitectural proteins, as well as blood breakdown proteins, and a few mitochondrial proteins. A unique as yet to be characterized peptide was found at m/z (mass/charge) 4733.5, which may represent a novel biomarker of metabolic distress. Conclusion Metabolic distress after TBI is associated with a differential proteome that indicates cellular destruction during the acute phase of illness. This suggests that metabolic distress has immediate cellular consequences after TBI.

show abstract

“…Proteomic databases have proven to be effective tools in basic and applied stem cell research as they facilitate the identification of changes in signal transduction components [25] with regard to plasticity, proliferation, or differentiation [19,26,27]. The knowledge of the cellular proteome also provides a useful instrument for the assessment of differential protein expression changes under disease conditions, for the analysis of functional protein interactions, and for the clinical treatment protocols [28,29]. These possibilities emphasize the necessity of a reliable and verifiable protein analysis as the basis of a proteomic reference database.…”

Section: Introductionmentioning

confidence: 99%

Stem cell proteomes: A profile of human mesenchymal stem cells derived from umbilical cord blood

et al. 2005

Self Cite

View full text Add to dashboard Cite

Multipotent mesenchymal stem cells (MSCs) derived from human umbilical cord blood (UCB) represent promising candidates for the development of future strategies in cellular therapy. To create a comprehensive protein expression profile for UCB-MSCs, one UCB unit from a full-term delivery was isolated from the unborn placenta, transferred into culture, and their whole-cell protein fraction was subjected to two-dimensional electrophoresis (2-DE). Unambiguous protein identification was achieved with peptide mass fingerprinting matrix-assisted laser desorption/ionization - time of flight - mass spectrometry (MALDI-TOF-MS), peptide sequencing (MALDI LIFT-TOF/TOF MS), as well as gel-matching with previously identified databases. In overall five replicate 2-DE runs, a total of 2037 +/- 437 protein spots were detected of which 205 were identified representing 145 different proteins and 60 isoforms or post-translational modifications. The identified proteins could be grouped into several functional categories, such as metabolism, folding, cytoskeleton, transcription, signal transduction, protein degradation, detoxification, vesicle/protein transport, cell cycle regulation, apoptosis, and calcium homeostasis. The acquired proteome map of nondifferentiated UCB-MSCs is a useful inventory which facilitates the identification of the normal proteomic pattern as well as its changes due to activated or suppressed pathways of cytosolic signal transduction which occur during proliferation, differentiation, or other experimental conditions.

show abstract

The proteome of human brain microdialysate

Cited by 60 publications

References 30 publications

Monitoring of the first stages of bone healing with microdialysis

Monitoring of the first stages of bone healing with microdialysis

Metabolic Crisis After Traumatic Brain Injury is Associated with a Novel Microdialysis Proteome

Stem cell proteomes: A profile of human mesenchymal stem cells derived from umbilical cord blood

Contact Info

Product

Resources

About